Investors in RxSight reminded of approaching Class Action lawsuit, with lead plaintiff deadline set for September 22, 2025 - RXST by law firm Faruqi & Faruqi.
RxSight, Inc. (NASDAQ: RXST), a medical device company, is under investigation for potential violations of federal securities laws. The law firm Faruqi & Faruqi, LLP is investigating potential claims against the company.
Between November 7, 2024, and July 8, 2025, RxSight reportedly overstated the demand for their products and failed to disclose adoption challenges and structural issues. This revelation came as the company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint.
The stock price of RxSight fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, following these announcements. The decline occurred on unusually heavy trading volume.
In a statement, Ronald Kurtz, the CEO of RxSight, acknowledged "adoption challenges over the last few quarters have been a primary reason for the LDD stall." The company also reported significant declines in LDD sales, LAL utilization, and overall revenue in the second quarter of 2025.
Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek the role of lead plaintiff in a federal securities class action against RxSight is September 22, 2025.
Faruqi & Faruqi, LLP, a leading national securities law firm, encourages anyone with information regarding RxSight's conduct to contact the firm. The firm can be reached through partner Josh Wilson, who can be contacted directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
For updates on this investigation, follow Faruqi & Faruqi on LinkedIn, X, or Facebook. More information about the RxSight class action can be found at www.faruqilaw.com/RXST.
It is important to note that the name of the prosecutor investigating RxSight for suspected violations of US securities laws is not publicly disclosed.
A photo accompanying this announcement is available at https://www.our website/NewsRoom/AttachmentNg/3a3fa937-87cb-45e3-b706-966046064eee.
Investors who purchased or acquired securities in RxSight between the specified dates are encouraged to contact Faruqi & Faruqi partner Josh Wilson.
Read also:
- Nightly sweat episodes linked to GERD: Crucial insights explained
- Antitussives: List of Examples, Functions, Adverse Reactions, and Additional Details
- Asthma Diagnosis: Exploring FeNO Tests and Related Treatments
- Unfortunate Financial Disarray for a Family from California After an Expensive Emergency Room Visit with Their Burned Infant
